The capitalization of export opportunities in regulated and semi-regulated markets was the way forward for the Indian pharmaceutical sector. The government's ease of driving policy should benefit several Indian drug manufacturers.
Government News
-
-
Antibiotic resistance is the result of environmental and behavioral causes. Indiscriminate antibiotic prescribing and lax enforcement laws are the main causes of antimicrobial resistance. This may be due to reckless use of antibiotics in hospitals as well as in private practice outside the easy availability of prescription drugs in the country.
-
Hundreds of scientists and academics from around the world are offering laboratory and office space to researchers stranded by the U.S. travel ban.
-
According to information provided by the Medical Council of India, there are a total of 9,88,922 allopathic doctors registered with the state medical council or MCI as of June 30, 2016.
-
The Union health ministry has notified the Medical Devices Rules, 2017. The rules will come into effect from January 1, 2018. This rule has been introduced for the first time in the world.
-
NPPA issues revised internal guidelines on discontinuation of production of scheduled formulations under paragraph 21 (2) of the DPCO, 2013.
-
The life sciences sector had high expectations of the budget not only from the point of view of tax incentives, but also from a regulatory point of view. Expectations were based on the Government's vision of making India one of the top three pharmaceutical markets by 2020. This year too, no specific impetus was given to the sector.
-
Tuberculosis is without doubt a deadly disease that requires serious and constant attention. To address the growing incidence of drug-resistant tuberculosis, its survivors and various public health groups have written to the Department of Health for the incorporation of the patented drug Delamanid into the RNTCP(Revised National Tuberculosis Control Programme). Delamanid has been shown to be effective in the treatment of drug-resistant TB. In a letter to the Union Ministry of Health, the organizations urged the government to order Ostuka Pharmaceuticals Co. Ltd. (Otsuka), the company holding the drug monopoly, to register the delamanid in India without further delay.
-
The health ministry asked the Supreme Court to challenge an order of the Delhi High Court that had quashed its ban on more than 300 fixed-dose drugs. The health ministry last year had banned 344 FDCs, estimated to affect about 6,000 drug brands and shave over Rs 3,000 crore on the Indian pharmaceutical market, which is estimated to be over Rs 100,000 crore.
[adsense:336x280:8701650588]
-
Union Minister for Chemicals & Fertilizers and Parliamentary Affairs, Shri Ananth Kumar presided over the signing of Memorandum of Understanding (MoU) between the Bureau of Pharma PSUs of India (BPPI) and National Yuva Cooperative Society Ltd. (NYCS) here today, with the objective to setup 1000 Pradhan Mantri Bhartiya Janaushadhi Kendras in both urban and rural places of the country, as a part of "Mission 3000" kendras by March 2017. Shri Mansukh L. Mandaviya, Minister of State for Road Transport & Highways, Shipping, Chemicals & Fertilizers, was also present on the occasion.
RECOMMENDED POSTS
Subscribe with us
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
